<?xml version="1.0" encoding="UTF-8"?>
<p>His height was 167.5 cm, the body weight was 50.2 kg and the SpO2 was 90%. His respiratory test results are shown in 
 <xref rid="T2" ref-type="table">Table 2</xref>. He was treated with nintedanib ethanesulfonate and 7.5 g (divided into 2 daily doses) of ninjin'yoeito. CFS decreased from 27 before administration to 16 and 24 after 4 and 12 weeks of administration, respectively, showing improvement. The mMRC scale was three before administration and 2 and 3 after 4 and 12 weeks of administration, respectively, showing no deterioration. The SNAQ score was 14 before administration and after 4 and 12 weeks of administration, showing no change. Body weight increased from 50.2 kg before administration to 50.4 and 51.9 kg after 4 and 12 weeks of administration, respectively. The blood albumin level was 4.1 g/dL before administration to 4.1 and 4.3 g/dL after 4 and 12 weeks of administration, respectively, showing an increasing trend. The Hb level increased from 12.8 g/dL before administration to 13.7 and 14.3 g/dL after 4 and 12 weeks of administration, respectively. The CONUT score could not be measured because the serum cholesterol levels were not measured. The levels of albumin and lymphocyte counts were normal throughout the treatment period. A trend for improvement was also observed with respect to respiratory function. Serum KL-6 decreased slightly from 496 to 492 U/ml. LDH decreased from 201 to 196 IU/L (
 <xref rid="T2" ref-type="table">Table 2</xref>). There was no occurrence of transaminitis during the treatment. A 6MWT after 14 weeks of administration showed improvement in the lowest SpO2 (from 87 to 91%) while the walking distance decreased from 360 to 300 m. The CT finding did not show significant changes before and after treatment with ninjin'yoeito.
</p>
